A pineal gland tripeptide studied for neuroprotection and circadian rhythm regulation.
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, or EDR) developed by Dr. Khavinson's group as a bioregulator of the pineal gland. The pineal gland produces melatonin and other neurological regulators important for circadian rhythm, sleep, and brain aging. Pinealon is designed to restore pineal and neurological bioregulation that declines with age.
The Khavinson bioregulator peptide system proposes that short oligopeptides derived from specific tissues can restore normal gene expression and cellular function in those tissues — a process called 'chromatin remodeling by short peptides.' Pinealon's EDR sequence is claimed to enter neurons and influence gene expression relevant to neuroprotection.
Research on Pinealon is primarily from Khavinson's group and Russian institutions. It is part of a system of tissue-specific bioregulators (others include Epithalon for pineal, Thymalin for thymus, etc.) marketed as a comprehensive aging intervention package.
Animal studies suggest Pinealon protects neurons from oxidative damage, improves learning and memory in aging models, and may reduce the accumulation of age-related neurotoxic substances. Circadian rhythm normalization has been studied.
Human data is limited to observations from Russian clinical practice. Published papers from Khavinson's institution show favorable effects, but independent Western validation is absent.
📚 Key Reference: PMID: 22780947 (Pinealon neuroprotection)
Limited data but no significant adverse events reported in Russian clinical use. Short peptides generally have low toxicity. Consult your provider.
NOT FDA-approved. Research use. Part of the Russian bioregulator peptide system. Available through some anti-aging specialty compounders.